- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00623441
E-Five Registry: A World-Wide Registry With The Endeavor Zotarolimus Eluting Coronary Stent (eFive)
26. oktober 2015 opdateret af: Medtronic Bakken Research Center
E-Five Registry: To Evaluate the 'Real World' Clinical Performance of the Medtronic Endeavor ABT-578 Eluting Coronary Stent System; A Prospective, Multicenter Registry
The safety and efficacy of the Endeavor(TM) ABT-578 Eluting Coronary Stent System has been assessed in a series of studies. The stent is coated with a proprietary drug compound that is designed to reduce restenosis.
This prospective multi-center study has been initiated:
- To document the acute and mid-term safety and overall clinical performance of the stent system in a "real world" patient population requiring stent implantation.
- To assess the event rate in patient subgroups with specific clinical indications and/or vessel or lesion characteristics.
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Undersøgelsestype
Observationel
Tilmelding (Faktiske)
8314
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Prøveudtagningsmetode
Ikke-sandsynlighedsprøve
Studiebefolkning
Real-world patients requiring drug eluting stent implantation
Beskrivelse
Inclusion Criteria:
- Patient is >18 years of age (or minimum age as required by local regulation)
- The patient has consented to participate by signing the "Patient Informed Consent Form" and/or has authorized the collection and release of his medical information by signing the "Patient Data Release Consent Form".
- The patient is suitable for implantation of one or more Endeavor(TM) ABT-578 Eluting Coronary Stent System in one or more native artery target lesions.
- Lesion length and vessel diameter of the target lesion(s) are according to the "Indications for Use" as mentioned in the "Instructions for Use" that comes with every Endeavor(TM) ABT-578 Eluting Coronary Stent System.
- The patient is willing and able to cooperate with registry procedures and required follow up visits.
Exclusion Criteria:
- Women with known pregnancy or who are lactating.
- Patients with hypersensitivity or allergies to aspirin, heparin, clopidogrel, ticlopidine, drugs such as ABT-578, rapamycin, tacrolimus, sirolimus or similar drugs, or any other analogue or derivative, cobalt, chromium, nickel, molybdenum or contrast media.
- Patients in whom anti-platelet and/pr anticoagulation therapy is contraindicated.
- Patients who are judged to have a lesion that prevents complete inflation of an angioplasty balloon.
- Current medical condition with a life expectancy of less than 12 months.
- The subject is participating in another device or drug study. Subject must have completed the follow-up phase of any previous study at least 30 days prior to enrollment in this trial. The subject may only be enrolled in this E-five registry once.
- Patients with medical conditions that preclude the follow-up as defined in the protocol or that otherwise limits participation in this registry.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
MACE (Major Adverse Cardiac Events)
Tidsramme: 12 Months
|
MACE is defined as death, myocardial infarction (Q-wave and non-Q wave), emergent cardiac bypass surgery, or target lesion revascularization (repeat PTCA (Percutaneous Transluminal Coronary Angioplasty) or CABG (Coronary Artery Bypass Graft surgery))
|
12 Months
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Efterforskere
- Ledende efterforsker: Ian T Meredith, MD, Monash Medical Centre, Melbourne, Australia
- Ledende efterforsker: Chaim Lotan, MD, Hadassah University Hospital, Jerusalem, Israel
- Ledende efterforsker: Martin T Rothman, MD, London Chest Hospital, London, United Kingdom
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Generelle publikationer
- Remak E, Manson S, Hutton J, Brasseur P, Olivier E, Gershlick A. Cost-effectiveness of the Endeavor stent in de novo native coronary artery lesions updated with contemporary data. EuroIntervention. 2010 Feb;5(7):826-32. doi: 10.4244/eijv5i7a138.
- Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Munzel T, Popma JJ, Fitzgerald PJ, Bonan R, Kuntz RE; ENDEAVOR II Investigators. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation. 2006 Aug 22;114(8):798-806. doi: 10.1161/CIRCULATIONAHA.105.591206. Epub 2006 Aug 14.
- Jain AK, Meredith IT, Lotan C, Rothman MT, Pateraki S; E-Five Investigators. Real-world safety and efficacy of the endeavor zotarolimus-eluting stent: early data from the E-Five Registry. Am J Cardiol. 2007 Oct 22;100(8B):77M-83M. doi: 10.1016/j.amjcard.2007.08.026.
- Lotan C, Meredith IT, Mauri L, Liu M, Rothman MT; E-Five Investigators. Safety and effectiveness of the Endeavor zotarolimus-eluting stent in real-world clinical practice: 12-month data from the E-Five registry. JACC Cardiovasc Interv. 2009 Dec;2(12):1227-35. doi: 10.1016/j.jcin.2009.10.001. Erratum In: JACC Cardiovasc Interv. 2010 Feb;3(2):264.
- Jain AK, Lotan C, Meredith IT, Feres F, Zambahari R, Sinha N, Rothman MT; E-Five Registry Investigators. Twelve-month outcomes in patients with diabetes implanted with a zotarolimus-eluting stent: results from the E-Five Registry. Heart. 2010 Jun;96(11):848-53. doi: 10.1136/hrt.2009.184150.
- Meredith I, Rothman M, Erglis A, Parikh K, Lotan C; E-Five Investigators. Extended follow-up safety and effectiveness of the Endeavor zotarolimus-eluting stent in real-world clinical practice: two-year follow-up from the E-Five Registry. Catheter Cardiovasc Interv. 2011 Jun 1;77(7):993-1000. doi: 10.1002/ccd.22803. Epub 2010 Dec 3.
- Lotan C, Meredith IT, Jain A, Feres F, Firszt A, Garcia AF, Rothman MT. Clinical outcomes by geographic region for patients implanted with the zotarolimus-eluting stent. Arq Bras Cardiol. 2011 May;96(5):353-62. doi: 10.1590/s0066-782x2011005000033. Epub 2011 Apr 1. English, Portuguese, Spanish.
- Kandzari DE, Leon MB, Popma JJ, Fitzgerald PJ, O'Shaughnessy C, Ball MW, Turco M, Applegate RJ, Gurbel PA, Midei MG, Badre SS, Mauri L, Thompson KP, LeNarz LA, Kuntz RE; ENDEAVOR III Investigators. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol. 2006 Dec 19;48(12):2440-7. doi: 10.1016/j.jacc.2006.08.035. Epub 2006 Nov 28.
Hjælpsomme links
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. september 2005
Primær færdiggørelse (Faktiske)
1. november 2007
Studieafslutning (Faktiske)
1. februar 2009
Datoer for studieregistrering
Først indsendt
18. februar 2008
Først indsendt, der opfyldte QC-kriterier
25. februar 2008
Først opslået (Skøn)
26. februar 2008
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
23. november 2015
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
26. oktober 2015
Sidst verificeret
1. oktober 2015
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- Protocol Final version1.1
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Koronararteriesygdom
-
IRCCS Policlinico S. DonatoRekrutteringAnomalous aorta origin of the coronary artery (AAOCA)Italien
-
University Hospital OstravaRekrutteringIn-Stent Carotis Artery RestenosisTjekkiet
-
Sohag UniversityIkke rekrutterer endnuUmblical artery Doppler under terminsgraviditetEgypten
-
Inova Health Care ServicesBoston Scientific CorporationAfsluttetKoronar angiografi | Transradial adgang | Radial arterie Intimal Medial Tykkelse | Distal Radial Artery Access (dTRA)Forenede Stater
-
Baylor College of MedicineAfsluttetLungeblødning | MAPCA - Major Aortopulmonary Collateral ArteryForenede Stater
-
Daewoong Pharmaceutical Co. LTD.UkendtMCA - Middle Cerebral Artery DissektionKorea, Republikken
-
Resicardunion nationale de formation et d'evaluation en medecine cardio-vasculaireAfsluttetHjertefejl | Akut koronarsyndrom | Koronar bypass-graft Stenose af Native Artery GraftFrankrig
-
AldagenUkendtSlag | Iskæmisk slagtilfælde | Slagtilfælde i Middle Cerebral Artery (MCA)Forenede Stater
Kliniske forsøg med Endeavor Zotarolimus Eluting Coronary Stent
-
Medtronic VascularAfsluttetKoronararteriesygdom, autosomal dominant, 1Forenede Stater
-
Medtronic VascularAfsluttetKoronararteriesygdomKorea, Republikken, Spanien, Australien, Hong Kong, Det Forenede Kongerige, Singapore, Thailand, Belgien, New Zealand, Sverige, Frankrig, Schweiz, Holland, Italien, Slovakiet, Litauen, Østrig, Malaysia, Bulgarien, Irland, Letland, ... og mere
-
Medical University of ViennaAfsluttet
-
Medtronic VascularAfsluttet
-
Chonnam National University HospitalAfsluttetMyokardieiskæmi | Koronararteriesygdom | Koronar sygdomKorea, Republikken
-
Sydney South West Area Health ServiceUkendtKoronar angioplastik og stenting | Single de Novo koronararteriestenoserAustralien
-
Seoul National University HospitalMedtronicUkendtMyokardieinfarkt | Koronararteriesygdom | Hjertekrampe | Akut koronarsyndromKorea, Republikken
-
Medtronic VascularAfsluttetMyokardieiskæmi | Hjerte-kar-sygdomme | Koronararteriesygdom | Arterielle okklusive sygdommeJapan
-
Conor MedsystemsAfsluttet
-
Genoss Co., Ltd.RekrutteringKoronararteriesygdom | Stent til eluering af lægemidlerKorea, Republikken